Penserra Capital Management LLC Prothena Corp Public LTD CO Transaction History

Penserra Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$48.26 - $78.59 $149,799 - $243,943	3,104 New	3,104 $211,000
Q4 2021 Feb 15, 2022	SELL	$42.11 - $73.26 $43,373 - $75,457	-1,030 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$48.2 - $78.89 $1,205 - $1,972	25 Added 2.49%	1,030 $73,000
Q2 2021 Aug 12, 2021	BUY	$21.63 - $57.65 $2,271 - $6,053	105 Added 11.67%	1,005 $51,000
Q1 2021 May 13, 2021	SELL	$11.0 - $28.24 $165 - $423	-15 Reduced 1.64%	900 $22,000
Q4 2020 Feb 12, 2021	BUY	$10.12 - $13.94 $5,839 - $8,043	577 Added 170.71%	915 $10,000
Q3 2020 Nov 13, 2020	BUY	$9.93 - $13.47 $3,356 - $4,552	338 New	338 $3,000

186

42.8M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $646M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.